anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
EDECRIN acts on the ascending limb of the loop of Henle and on the proximal and distal tubules. Urinary output is usually dose dependent and related to the magnitude of fluid accumulation. Water and electrolyte excretion may be increased several times over that observed with thiazide diuretics, since EDECRIN inhibits reabsorption of a much greater proportion of filtered sodium than most other diuretic agents. Therefore, EDECRIN is effective in many patients who have significant degrees of renal insufficiency (see WARNINGS concerning deafness). EDECRIN has little or no effect on glomerular filtration or on renal blood flow, except following pronounced reductions in plasma volume when associated with rapid diuresis.

The electrolyte excretion pattern of ethacrynic acid varies from that of the thiazides and mercurial diuretics. Initial sodium and chloride excretion is usually substantial and chloride loss exceeds that of sodium. With prolonged administration, chloride excretion declines, and potassium and hydrogen ion excretion may increase. EDECRIN is effective whether or not there is clinical acidosis or alkalosis.

Although EDECRIN, in carefully controlled studies in animals and experimental subjects, produces a more favorable sodium/potassium excretion ratio than the thiazides, in patients with increased diuresis excessive amounts of potassium may be excreted.

Onset of action is rapid, usually within 30 minutes after an oral dose of EDECRIN or within 5 minutes after an intravenous injection of SODIUM EDECRIN. After oral use, diuresis peaks in about 2 hours and lasts about 6 to 8 hours.

The sulfhydryl binding propensity of ethacrynic acid differs somewhat from that of the organomercurials. Its mode of action is not by carbonic anhydrase inhibition.

Ethacrynic acid does not cross the blood-brain barrier.
Although the end of the critical phase of the COVID-19 pandemic has been declared, its consequences are still observed in the general population and some categories of workers. HCWs have had to face the battle against this disease on the front lines. In our study, we evaluated the current state of the consequences of the pandemic on compassion fatigue, loneliness, empathy, anxiety, and hopelessness in a group of 71 HCWs from a rehabilitation center. This data, collected in the time of May-June 2024 (T2), was compared in the same sample in 2020 (T0) and 2023 (T1). The results highlighted increased burnout (P-Bonferroni: 0.005) and feelings of loneliness in T2 (P-Bonferroni: 0.005). Importantly, the results of the compassion satisfaction remained stable, providing reassurance about the resilience of HCWs. Secondary Trauma results decreased in T2, indicating less psychological pressure associated with COVID-19 pathology.
The present invention relates to a Chinese traditional patent medicine for treating chloasma, which takes more than 10 traditional Chinese medicines of Chinese thorowax root, Chinese angelica, red paeony root, salvia miltiorrhiza, radix rehmanniae glutinosae etc. as the raw materials. The present invention has the effects of soothing liver, anti-depression and regulating qi and activating blood circulation. Based on the differential treatment of the traditional Chinese medicine, the invention is developed by combining the latest scientific research results with the traditional Chinese medicine. The present invention aims at providing the Chinese traditional patent medicine to treat chloasma. The present invention is characterized by accurate efficacy, safety, convenience, no toxicity or side effects and low price.
The invention belongs to drinks field, a kind of manufacture craft of Maca wine is specifically disclosed, is comprised the following steps：A. material is prepared；B. decoction is boiled；C. Maca wine semi-finished product are obtained；D. store sth. in a cellar；E. periodically displacement；F. Maca wine finished wine is obtained.This programme can check the sealing for storing up wine device during being shifted to storage wine device, to be remedied in time, it is ensured that the sealing of storage wine device, prevent that storing up quality of the wine device because of air inlet to Maca wine produces harmful effect；And the Maca wine made using this programme has effects that nourishing and fit keeping function, dehumidifying are dispelled hot, anti-heat diseases prevention, and there can be nourishing and fit keeping function the extracts active ingredients of agate card into wine to human body, can also be drunk even if the people got angry.
PURPOSE: To report a case of bilateral ciliochoroidal effusion syndrome associated with sildenafil use.
CASE REPORT: A 41-year-old male presented with a five-day history of bilateral blurred vision, elevated intraocular pressure, and myopic shift. Ultrasound biomicroscopy radial scans showed closed angles and 360 degrees of ciliochoroidal effusion in both eyes. Anterior segment coherence tomography angiography showed bilateral shallow anterior chamber. Further questioning revealed that the patient had taken sildenafil several times just a few days before symptoms appeared. Since then, the patient stopped dosing sildenafil. After treatment of anti-inflammation and shifting the lens-iris diaphragm posteriorly, the patient's visual acuity improved and intraocular pressure decreased. Follow-up ultrasound biomicroscopy and anterior segment coherence tomography angiography revealed resolution of ciliochoroidal effusion and increase of anterior chamber depth in both eyes.
CONCLUSIONS: The patient demonstrated a rare case of sildenafil-induced bilateral ciliochoroidal effusion syndrome. This case report shows that sildenafil should be added to the possible causative agents of ciliochoroidal effusion syndrome.
Invention relates to medicinal agent used for correction of metabolic vascular syndrome and diseases accompanying with vascular wall penetrability disorder and capillaries fragility and can be used as agent enhancing resistance of capillaries. Invention proposes peptide lysyl-glutamyl-aspartic acid of the general formula: H-Lys-Glu-Asp-OH corresponding to the sequence 1 [SEQ ID NO:1] possessing biological activity and eliciting enhancing effect on resistance of capillaries. Also, invention proposes pharmaceutical composition enhancing resistance of capillaries and containing effective amount of peptide lysyl-glutamyl-aspartic acid of the general formula: H-Lys-Glu-Asp-OH of the sequence 1 [SEQ ID NO:1] as an active component and a pharmaceutically acceptable carrier. Pharmaceutical composition is prepared in form suitable for parenteral administration. Also, invention proposes a method for prophylaxis and/or treatment of microcirculation disorders in organs and tissues and involves administration in patient pharmaceutical composition containing effective amount of peptide lysyl-glutamyl-aspartic acid of the general formula: H-Lys-Glu-Asp-OH of the sequence 1 [SEQ ID NO:1] as an active component in the dose 0.01-100 mcg/kg of body mass for at least once per a day for period necessary for providing the therapeutic effect. Administration is carried out by parenteral route.
Following a 12-day open-label treatment phase (involving ketamine and minocycline), responders may receive oral minocycline twice daily for up to 6 weeks in a blinded manner. In addition, non-responders may receive oral minocycline twice daily for up to 6 weeks in an open-label manner.
Retinoids, including VESANOID, have been associated with intracranial hypertension, especially in pediatric patients. Early signs and symptoms include papilledema, headache, nausea, vomiting, and visual disturbances. Evaluate patients with these symptoms for intracranial hypertension, and, if present, institute appropriate care in concert with neurological assessment. Consider interruption, dose reduction, or discontinuation of VESANOID as appropriate. 

The concomitant use of other products (e.g., tetracyclines) that can cause intracranial hypertension may increase the risk. Avoid concomitant use of VESANOID with other products that can cause intracranial hypertension [see Drug Interactions (7.2)].
PURPOSE:To obtain the subject application agent, containing a specified drug, and respective specific amounts of specific higher fatty acid ester and amide compound as the absorbefacient for the aforementioned drug in a tacky agent layer on a specified support and capable of maintaining a high blood level of the drug in a small area for a long period. CONSTITUTION:A sustained release percutaneous absorbable application agent, obtained by providing a tacky agent layer containing 1-42wt.% 4-(1-methyl-4- piperidylidene)-4H-benzo[4,5]cyclohepta[1,2-b]thiophen-10(9H)-one and/or a salt thereof useful as a medicine for allergic diseases and further (A) a 1-10C alcohol ester of a 10-18C higher fatty acid and (B) a compound having amide bond as the absorbefacient for the above-mentioned drug on a drug-impermeable support, having high skin permeability of the aforementioned drug with high treating effects and excellent in safety an feeling in the application. The amounts of the ingredients based on 100 pts.wt. tacky base are 1-150 pts.wt. ingredient (A) and 1-50 pts.wt. ingredient (B).
The invention discloses a fire treatment Chinese native medicine and western medicine liniment and a preparation method thereof. The liniment comprises a positive medicament and a negative medicament, wherein the positive medicament contains pseudo-ginseng root, rhizoma zingiberis, camphor, cortex lycii radices, earthworm, frankincense, aractylodes ovate, red chilli powder, farfugium japonicum, salvia miltiorrhiza and scorpio; and the negative medicament contains pseudo-ginseng root, honeysuckle flower, dyers woad leaf, rehmanniae, cassia twig, farfugium japonicum, borneol, muscone and scorpio. A fire treatment medicated wine liniment for treating cervical spondylosis, lumbar vertebra disease, arthralgia and traumatic injury pain is prepared by soaking the positive medicament and the negative medicament into alcohol, and dissolving the Chinese medicinal components into the soaking alcohol. A western medicinal anti-inflammation medicament is added into the fire treatment medicated wine liniment. The liniment is applied by dipping burning medicinal liquor with a hand, contacting the medicinal liquor with an affected part and massaging, so that muscles and pores can be rapidly expanded, and the medicament effect can go deep into skin, meridians and articulationes vertebrales. The liniment has the effects of clearing and activating channels and collaterals, activating blood circulation to dissipate blood stasis and rapidly relieving the pain. The liniment has a good healing effect, low cost and no toxic or side effect and is convenient to use.
The integrity of the intestinal mucus barrier is crucial for human health, as it serves as the body's first line of defense against pathogens. However, postnatal development of the mucus barrier and interactions between maturity and its ability to adapt to external challenges in neonatal infants remain unclear. In this study, we unveil a distinct developmental trajectory of the mucus barrier in preterm piglets, leading to enhanced mucus microstructure and reduced mucus diffusivity compared to term piglets. Notably, we found that necrotizing enterocolitis (NEC) is associated with increased mucus diffusivity of our large pathogen model compound, establishing a direct link between the NEC condition and the mucus barrier. Furthermore, we observed that addition of sodium decanoate had varying effects on mucus diffusivity depending on maturity and health state of the piglets. These findings demonstrate that regulatory mechanisms governing the neonatal mucosal barrier are highly complex and are influenced by age, maturity, and health conditions. Therefore, our results highlight the need for specific therapeutic strategies tailored to each neonatal period to ensure optimal gut health.
PURPOSE: Thyroid cancer has an overwhelming incidence in the population. Thus, there is an urgent need to understand the underlying mechanism of its occurrence and development, which may provide new insights into therapeutic strategies. The role and mechanism of TFCP2L1 in regulating the progression of thyroid cancer remains unclear.
METHODS: Public databases and clinical samples were used to detect the expression of TFCP2L1 in cancer and non-cancer tissues. Kaplan-Meier and Cox regression analyses were used to compare the differences in survival probability of the TFCP2L1 highly expressing group and the TFCP2L1 lowly expressing group. Functional assays were used to evaluate the biological effect of TFCP2L1 on thyroid cancer cells. RNA sequencing and enrichment analyses were used to find out pathways that were activated or inactivated by TFCP2L1.
RESULTS: We demonstrated that TFCP2L1 was significantly downregulated in thyroid cancer. Decreased expression of TFCP2L1 was associated with malignant clinicopathological characteristics. Kaplan-Meier and Cox regression analyses indicated that thyroid tumor patients with low TFCP2L1 expression presented shorter disease-free interval and progression-free interval. Additionally, TFCP2L1 expression was positively correlated with thyroid differentiation degree. Overexpression of TFCP2L1 in thyroid cancer cells inhibited cell growth and motility in vitro, and tumorigenicity and metastasis in vivo. Mechanistically, the NF-κB signaling pathway was found inactivated by overexpressing TFCP2L1.
CONCLUSION: Our results suggest that TFCP2L1 is a tumor suppressor and potential differentiation regulator, and might be a potential therapeutic target in thyroid cancer.
FIELD: medicine, stomatology. SUBSTANCE: one should carry out osteogingivoplasty at introducing resorbed membrane into parodontal pouch. "Diplen" film is applied as such resorbed membrane. This film is applied onto osseous defect by its hydrophilic side. Moreover, the film should be used at the size overlapping osseous defect from both vestibular and approximate sides by 3 mm, as minimum. The suggested method enables to safe the cavity of osseous defect against soft tissues penetration that leads to target tissue regeneration. EFFECT: higher efficiency. 1 ex
1. Technical Result Increase in stability of cyclosporin formulations and simplification of their storage conditions.           2. Essence An oral cyclosporin formulation comprises cyclosporin, at least one alkanol solvent of from 2 to 3 carbon atoms, at least one non-ionic polyoxialkylen surfactant, As a surfactant it comprises a compound selected from the polyoxiethylene spirits and monoesters of ethoxylated polyols of fat acids comprising 4-6 carbon atoms.           In order to obtain the cyclosporin suspension, it is mixed with the alkanol solvent comprising 2 to 3 carbon atoms and with the non-ionic polyoxialkylen surfactant. The obtained concentrated solvent is diluted by water.          3. Field of Application Medicine.
OBJECTIVES: To evaluate the bacterial biofilm's role in mucosal chronic suppurative otitis media (CSOM) utilizing scanning electron microscopy (SEM).
METHODS: This study involved 123 participating patients with active and inactive mucosal CSOM who underwent tympanomastoid surgery. SEM was used to examine middle ear mucosa biopsies for the development of biofilms. Middle ear discharge or mucosal swabs from patients were cultured to detect any bacterial growth. The biofilm formation was correlated to the culture results.
RESULTS: The biofilm was present in 69.9 % of patients (59% of them were with active mucosal CSOM) and absent in 30.1% of the patients (70% of them were with inactive mucosal CSOM), being more statistically significant in active mucosal CSOM (p-value = 0.003). A correlation that was statistically significant was found between active mucosal CSOM and higher grades (3 and 4) of biofilms (p-value <0.05). The mucosal CSOM type and the results of the culture had a relationship that was statistically significant (p-value <0.001). 60% of patients had positive culture (70% of them were with active mucosal CSOM). There was a statistically significant relation between Pseudomonas aeruginosa bacterial growth and active mucosal CSOM (p-value = 0.004) as well as higher grades of biofilms in mucosal CSOM.
CONCLUSION: Mucosal CSOM, especially the active type, is a biofilm-related disease. There is a significant relation between the state of mucosal CSOM (active or inactive) and culture results with predominance of Pseudomonas aeruginosa bacterial growth in active mucosal CSOM and in higher grades of biofilms in mucosal CSOM.
A medical support device distributes medical information of a patient to external terminals the supporters have, and shares comments from the supporters to support diagnosis and treatment of a doctor in charge of the patient. In the medical support device, an information sending section distributes the information to the external terminals. An information receiving section receives response information sent from the doctor or the supporter in response to the distributed information. A relation display controller displays the distributed and response information in a related manner. An importance determining section determines the degree of importance of the distributed information. When the degree of importance of the distributed information equals or exceeds a threshold value, a reception state setting section suspends transmission of new information from the external terminals and a hospital terminal and puts the terminals in a ready-to-receive state.
Alpha-synucleinopathies are prevalent neurological disorders that cause significant disability, leading to progressive clinical deterioration that is currently managed solely through symptomatic treatment. Efforts to evaluate disease-modifying therapies during the established stage of the disease have not yielded positive outcomes in terms of clinical or imaging efficacy endpoints. However, alpha-synucleinopathies have a long prodromal phase that presents a promising opportunity for intervention with disease-modifying therapies. The presence of polysomnography-confirmed REM sleep behavior disorder (RBD) is the most reliable risk factor for identifying individuals in the prodromal stage of alpha-synucleinopathy. This paper discusses the rationale behind targeting idiopathic/isolated RBD in disease-modifying trials and outlines possible study designs, including strategies for patient stratification, selection of biomarkers to assess disease progression and patient eligibility, as well as the identification of suitable endpoints. Additionally, the potential targets for disease-modifying treatment in alpha-synucleinopathies are summarized.
Background: Tonsillectomy is a common surgery in the US, with possible postoperative complications. While small studies indicate postoperative depressive symptoms may occur, large-scale evidence is lacking on the tonsillectomy-depression link. Methods: We conducted a retrospective cohort study using the TriNetX US collaborative network, offering de-identified electronic health data from 59 collaborative healthcare organizations (HCOs) in the United States. In this study, people being diagnosed of chronic tonsillitis between January 2005 and December 2017 were enrolled. Patients deceased, with previous record of cancers or psychiatric events before index date were excluded. 14,874 chronic tonsillitis patients undergoing tonsillectomy were propensity score matched 1:1 to controls for age, sex, and race. New-onset depression risks were evaluated over 5 years post-tonsillectomy and stratified by age and sex. Confounders were adjusted for including demographics, medications, comorbidities and socioeconomic statuses. Results: After matching, the difference of key baseline characteristics including age, sex, comedications status and obesity status was insignificant between tonsillectomy and non-tonsillectomy groups. Tonsillectomy had a 1.29 times higher 5-year depression risk versus matched controls (95% CI, 1.19-1.40), with elevated risks seen at 1 year (HR=1.51; 95% CI, 1.28-1.79) and 3 years (HR=1.30; 95% CI, 1.18-1.43). By stratifications, risks were increased for both males (HR=1.30; 95% CI, 1.08-1.57) and females (HR=1.30; 95% CI, 1.18-1.42), and significantly higher in ages 18-64 years (HR=1.37; 1.26-1.49), but no significance observed for those 65 years and older. After performing sensitivity analyses and applying washout periods of 6, 12, and 36 months, the outcome remained consistent with unadjusted results. Conclusion: This real-world analysis found tonsillectomy was associated with a 30% higher 5-year depression risk versus matched non-tonsillectomy patients with chronic tonsillitis. Further mechanistic research is needed to clarify the pathophysiologic association between depression and tonsillectomy. Depression is not commonly mentioned in the current post-tonsillectomy care realm; however, the outcome of our study emphasized the possibility of these suffering condition after operation. Attention to psychological impacts following tonsillectomy is warranted to support patient well-being, leading to better management of post-tonsillectomy individuals.
Proteinuria and nephrotic syndrome have been reported. Some of these cases have resulted in renal failure and fatal outcomes.

Monitor patients for the development or worsening of proteinuria. Perform baseline and periodic urinalyses during treatment, with follow up measurement of 24-hour urine protein as clinically indicated. Interrupt sunitinib and dose reduce for 24-hour urine protein of 3 or more grams. Discontinue sunitinib for patients with nephrotic syndrome or repeat episodes of 24-hour urine protein 3 or more grams despite dose reductions. The safety of continued sunitinib treatment in patients with moderate to severe proteinuria has not been evaluated.
The subjects in arms A and B will receive auricular acupuncture. The subjects in arms A will receive auricular acupuncture (at 2nd and 4th chemotherapy courses) as well as the sham auricular acupuncture (at the 3rd chemotherapy course).
The lymphatic fluid is the conduit by which part of the tissue "omics" is transported to the draining lymph node for immunosurveillance. Following cannulation of the pre-nodal cervical and mesenteric afferent lymphatics, herein we investigate the lymph proteomic composition, uncovering that its composition varies according to the tissue of origin. Tissue specificity is also reflected in the dendritic cell-major histocompatibility complex class II-eluted immunopeptidome harvested from the cervical and mesenteric nodes. Following inflammatory disruption of the gut barrier, the lymph antigenic and inflammatory loads are analyzed in both mice and subjects with inflammatory bowel diseases. Gastrointestinal tissue damage reflects the lymph inflammatory and damage-associated molecular pattern signatures, microbiome-derived by-products, and immunomodulatory molecules, including metabolites of the gut-brain axis, mapped in the afferent mesenteric lymph. Our data point to the relevance of the lymphatic fluid to probe the tissue-specific antigenic and inflammatory load transported to the draining lymph node for immunosurveillance.